Physiology

• One day, she explained that she adds apple cider vinegar to improve my health.
• Apple cider vinegar is a natural product made of fermented apple juice that has gone sour.
• I decided to turn medical sleuth and investigate whether apple cider vinegar is as good for health as it sounds.

Claim: disinfectant properties

• But does apple cider vinegar’s decontaminant qualities translate to the human gut?
• Our stomachs produce acid, which acts as a natural barrier to infection, so how can adding more acid help?

Claim: weight loss and management of type 2 diabetes

• There are plenty of anecdotal claims that apple cider vinegar can aid weight loss, supported by limited evidence from several small studies.
• Apple cider vinegar is thought to cause weight loss through its effect on delay of gastric emptying.
• Reduced calorific intake will lead to weight loss – but how are the metabolic effects on blood glucose and lipids mediated?
• In type 2 diabetes there is a reduction in sensitivity to insulin which in turn leads to a reduced uptake of glucose by cells.

Claim: reduces risk of heart disease

• Raised blood lipids are a risk factor for cardiovascular diseases such as myocardial infarction and stroke.
• Well, I’m afraid there’s no scientific evidence that vinegar consumption of any kind reduces cardiovascular morbidity and mortality in those with or without diabetes.

Claim: cancer treatment and prevention

• One of the more outrageous claims of benefits of daily apple cider vinegar consumption is that it may prevent or treat cancer.
• A frequently quoted case-control study from China found that an increased consumption of vinegar was associated with a reduced incidence of oesophageal cancer.

Stephen Hughes does not work for, consult, own shares in or receive funding from any company or organisation that would benefit from this article, and has disclosed no relevant affiliations beyond their academic appointment.

• The registry will collect multi-site, real-world information on how the Plaque Analysis product provides enhanced patient insights, empowering physicians and helping to inform their medical management decisions for patients with suspected coronary artery disease (CAD).
• The DECODE study showed that clinicians using the HeartFlow Plaque Analysis changed their management decisions for 66% of patients compared to CCTA alone across various patient presentations and disease stages.
• “We believe real-world prospective data from the new DECIDE Registry will empower clinicians with enhanced patient insights leveraging HeartFlow Plaque Analysis to improve patient outcomes.
• The primary endpoint for this registry will highlight change in medical management after HeartFlow Plaque Analysis compared to after CCTA alone.

• Parker University is proud to announce that its graduate-level Strength and Conditioning program has been granted five years of initial accreditation status!
• Parker University’s Strength and Human Performance Program Director Jenna Romanelli, MS, Med, RD, CSC, says, “The CASCE accreditation directly reflects our Strength and Human Performance degree.
• Parker University’s degrees in Strength and Human Performance provide students with an expansive study of evidence-based research in physiology, biomechanics, and human metabolism to enhance health, function, and physical performance.
• Parker University is proud of its unwavering dedication to providing strength and conditioning education of the highest quality.

• KNOXVILLE, TN, March 12, 2024 (GLOBE NEWSWIRE) -- Provectus Biopharmaceuticals, Inc. (“Provectus” or the “Company”) (OTCQB: PVCT) today announced that the United States Patent and Trademark Office (“USPTO”) has allowed patent application 17/212,723, titled “Novel Uses of Halogenated Xanthenes in Oncology and Virology.” The application covers the use of Provectus’s pharmaceutical-grade rose bengal sodium (“RBS”) drug substance for the treatment of infectious diseases, such as coronaviruses.
• The USPTO has also allowed patent application 17/344,418, titled “In Vitro and Xenograft Anti-Tumor Activity of a Halogenated-Xanthene Against Refractory Pediatric Solid Tumors.” This prospective award covers the use of RBS in combination with one or more immune checkpoint inhibitors and is a continuation of U.S. patent 11,058,664 (2021), Provectus’s first for pediatric oncology.
• The Company’s previously allowed patent application 17/488,430, titled “Halogenated Xanthenes as Vaccine Adjuvants” (December 2023) and covering RBS’s use as an adjuvant in vaccines to potentially make them work better, will be awarded on March 26, 2024 as U.S. patent 11,938,182.
• Innovate Calgary, the innovation company of the University of Calgary in Alberta, Canada, is a co-assignee and Aru Narendran, MD, PhD, Professor of Pediatrics, Oncology, Biochemistry and Molecular Biology and Physiology and Pharmacology at the University’s Cumming School of Medicine is a co-inventor on all three patent awards.